Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

Detalles Bibliográficos
Autores principales: Khan, I., Kaempf, A., Raghuwanshi, S., Chesnokov, M., Zhang, X., Wang, Z., Domling, A., Tyner, J. W., Camacho, C., Gartel, A. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444844/
https://www.ncbi.nlm.nih.gov/pubmed/37607920
http://dx.doi.org/10.1038/s41408-023-00898-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444844/
https://www.ncbi.nlm.nih.gov/pubmed/37607920
http://dx.doi.org/10.1038/s41408-023-00898-4

Ejemplares similares